person · Reporting owner

Ridloff Elena

Disclosed activity across 5 companies

Tapewire entity: 24976
SEC CIK: 0001772518

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACADIA PHARMACEUTICALS INCACAD · Entity 3913	EVP and CFO	April 29, 2021	April 30, 2021
IMMUNIC, INC.IMUX · Entity 6306	Director	August 06, 2026	August 10, 2026
Kymera Therapeutics, Inc.KYMR · Entity 3545	Director	June 24, 2026	June 25, 2026
Sionna Therapeutics, Inc.SION · Entity 5996	CFO and CBO	September 17, 2026	September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACADIA PHARMACEUTICALS INC

Report date April 29, 2021 · Filed April 30, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,553	Ending reported balance After 2021-04-30 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2021-04-29 · Exercise / conversion · Acquired 3,245 · Balance 11,585 F1: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. Row 2 · 2021-04-30 · Sale · Disposed 1,032 · Balance 10,553 F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	6,491	Reported balance After 2021-04-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-04-29 · Exercise / conversion · Disposed 3,245 · Balance 6,491 F1: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3: The restricted stock units vest in four equal annual installments beginning 4/29/2020.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3: The restricted stock units vest in four equal annual installments beginning 4/29/2020.

IMMUNIC, INC.

Report date August 06, 2026 · Filed August 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.54 · Expires 2036-08-06	Direct	50,740	Reported balance After 2026-08-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-08-06 · Grant · Acquired 50,740 · Balance 50,740 F1: The options vest in monthly increments over a period of three years from the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest in monthly increments over a period of three years from the grant date.

Kymera Therapeutics, Inc.

Report date June 24, 2026 · Filed June 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.87 · Expires 2036-06-23	Direct	6,068	Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-24 · Grant · Acquired 6,068 · Balance 6,068 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Sionna Therapeutics, Inc.

Report date September 17, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	133,069	Ending reported balance After 2026-09-17 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-17 · Grant · Acquired 47,269 · Balance 85,801 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest on June 17, 2027, subject to the Reporting Person's continued service with the Issuer as of the vesting date. Row 2 · 2026-09-17 · Grant · Acquired 47,268 · Balance 133,069 F2: Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest upon the achievement of a designated performance milestone, subject to the Reporting Person's continued service with the Issuer as of the vesting date.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.18 · Expires 2036-01-01	Direct	165,440	Reported balance After 2026-09-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-17 · Grant · Acquired 165,440 · Balance 165,440 F3: The exercise price of the option is $7.18 per share, representing the fair market value per share of the Issuer's Common Stock on September 17, 2026 (the "Repricing Date"). Unless otherwise provided by the Issuer's board of directors or its compensation committee, if the option is exercised before the applicable retention period ends, the exercise price will revert to its original exercise price. The retention period begins on the Repricing Date and ends on the earliest of (i) the 18-month anniversary of the Repricing Date (March 17, 2028), (ii) a Sale Event (as defined in the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the "2025 Plan")) or (iii) certain qualifying terminations of service. F4: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5: This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.21 · Expires 2036-01-01	Direct	0	Reported balance After 2026-09-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-17 · Disposition to issuer · Disposed 165,440 · Balance 0 F4: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5: This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest on June 17, 2027, subject to the Reporting Person's continued service with the Issuer as of the vesting date.

F2: Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest upon the achievement of a designated performance milestone, subject to the Reporting Person's continued service with the Issuer as of the vesting date.

F3: The exercise price of the option is $7.18 per share, representing the fair market value per share of the Issuer's Common Stock on September 17, 2026 (the "Repricing Date"). Unless otherwise provided by the Issuer's board of directors or its compensation committee, if the option is exercised before the applicable retention period ends, the exercise price will revert to its original exercise price. The retention period begins on the Repricing Date and ends on the earliest of (i) the 18-month anniversary of the Repricing Date (March 17, 2028), (ii) a Sale Event (as defined in the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the "2025 Plan")) or (iii) certain qualifying terminations of service.

F4: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5: This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Kronos Bio, Inc.

Report date June 20, 2025 · Filed June 20, 2025

Section 16 reporting ended · disclosed 2025-06-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-06-20 transaction · row 1 1 source row Row 1 · 2025-06-20 · Other · Disposed 25,296 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2030-09-10	Direct	Reported balance After 2025-06-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-06-20 · Disposition to issuer · Disposed 25,879 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2030-09-10	Direct	Reported balance After 2025-06-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-06-20 · Disposition to issuer · Disposed 26,871 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.18 · Expires 2031-06-21	Direct	Reported balance After 2025-06-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-06-20 · Disposition to issuer · Disposed 15,450 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.53 · Expires 2032-06-21	Direct	Reported balance After 2025-06-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2033-06-21	Direct	Reported balance After 2025-06-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-06-20 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2034-06-24	Direct	Reported balance After 2025-06-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-06-20 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 17, 2026 Filed Sep 18, 2026 20:59 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	165,440	$0.00 Strike: $39.21	$0.00	Disclosure SEC source: 0001772518-26-000004 · edgardoc.xml · derivative · entry 4 Ridloff Elena · CIK 0001772518 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 165,440 shares Expires 2036-01-01 F4 · kind: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · price: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
September 17, 2026 Filed Sep 18, 2026 20:59 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	GrantNon-Qualified Stock Option (right to buy) · Derivative	165,440	$0.00 Strike: $7.18	$0.00	Disclosure SEC source: 0001772518-26-000004 · edgardoc.xml · derivative · entry 3 Ridloff Elena · CIK 0001772518 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,440 Underlying: Common Stock · 165,440 shares Expires 2036-01-01 F3 · derivative.exercise_price: The exercise price of the option is $7.18 per share, representing the fair market value per share of the Issuer's Common Stock on September 17, 2026 (the "Repricing Date"). Unless otherwise provided by the Issuer's board of directors or its compensation committee, if the option is exercised before the applicable retention period ends, the exercise price will revert to its original exercise price. The retention period begins on the Repricing Date and ends on the earliest of (i) the 18-month anniversary of the Repricing Date (March 17, 2028), (ii) a Sale Event (as defined in the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the "2025 Plan")) or (iii) certain qualifying terminations of service. F4 · kind: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · price: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document
September 17, 2026 Filed Sep 18, 2026 20:59 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	GrantCommon Stock	47,268	$0.00	$0.00	Disclosure SEC source: 0001772518-26-000004 · edgardoc.xml · nonDerivative · entry 2 Ridloff Elena · CIK 0001772518 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,069 F2 · kind: Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest upon the achievement of a designated performance milestone, subject to the Reporting Person's continued service with the Issuer as of the vesting date. Read SEC document
September 17, 2026 Filed Sep 18, 2026 20:59 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	GrantCommon Stock	47,269	$0.00	$0.00	Disclosure SEC source: 0001772518-26-000004 · edgardoc.xml · nonDerivative · entry 1 Ridloff Elena · CIK 0001772518 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,801 F1 · kind: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest on June 17, 2027, subject to the Reporting Person's continued service with the Issuer as of the vesting date. Read SEC document
August 06, 2026 Filed Aug 10, 2026 23:00 UTC	IMMUNIC, INC. IMUX · Entity 6306	GrantStock Option · Derivative	50,740	$0.00 Strike: $14.54	$0.00	Disclosure SEC source: 0001193805-26-001069 · e665686_4-ridloff.xml · derivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,740 Underlying: Common Stock · 50,740 shares Expires 2036-08-06 F1 · derivative.exercise_date: The options vest in monthly increments over a period of three years from the grant date. Read SEC document
June 24, 2026 Filed Jun 25, 2026 22:00 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantStock Option (Right to Buy) · Derivative	6,068	$0.00 Strike: $99.87	$0.00	Disclosure SEC source: 0001193125-26-283138 · ownership.xml · derivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,068 Underlying: Common Stock · 6,068 shares Expires 2036-06-23 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document
May 11, 2026 Filed May 11, 2026 20:58 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	Exercise / conversionStock Option (Right to Buy) · Derivative	3,000	$0.00 Strike: $31.20	$0.00	Disclosure SEC source: 0001193125-26-217041 · ownership.xml · derivative · entry 3 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 3,000 shares Expires 2034-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document
May 11, 2026 Filed May 11, 2026 20:58 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	SaleCommon Stock	3,000	$87.00	$261,000.00	Disclosure SEC source: 0001193125-26-217041 · ownership.xml · nonDerivative · entry 2 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. Read SEC document
May 11, 2026 Filed May 11, 2026 20:58 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	Exercise / conversionCommon Stock	3,000	$31.20	$93,600.00	Disclosure SEC source: 0001193125-26-217041 · ownership.xml · nonDerivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. Read SEC document
April 01, 2026 Filed Apr 1, 2026 23:00 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	Exercise / conversionStock Option (Right to Buy) · Derivative	4,600	$0.00 Strike: $14.18	$0.00	Disclosure SEC source: 0001193125-26-138372 · ownership.xml · derivative · entry 7 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,600 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document
April 01, 2026 Filed Apr 1, 2026 23:00 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	SaleCommon Stock	1,200	$86.05	$103,260.00	Disclosure SEC source: 0001193125-26-138372 · ownership.xml · nonDerivative · entry 5 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. Read SEC document
April 01, 2026 Filed Apr 1, 2026 23:00 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	SaleCommon Stock	3,400	$85.19	$289,661.64	Disclosure SEC source: 0001193125-26-138372 · ownership.xml · nonDerivative · entry 4 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,200 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
April 01, 2026 Filed Apr 1, 2026 23:00 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	Exercise / conversionCommon Stock	4,600	$14.18	$65,228.00	Disclosure SEC source: 0001193125-26-138372 · ownership.xml · nonDerivative · entry 3 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. Read SEC document
March 31, 2026 Filed Apr 1, 2026 23:00 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	Exercise / conversionStock Option (Right to Buy) · Derivative	7,400	$0.00 Strike: $14.18	$0.00	Disclosure SEC source: 0001193125-26-138372 · ownership.xml · derivative · entry 6 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 7,400 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document
March 31, 2026 Filed Apr 1, 2026 23:00 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	SaleCommon Stock	7,400	$85.37	$631,738.74	Disclosure SEC source: 0001193125-26-138372 · ownership.xml · nonDerivative · entry 2 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.04 to $85.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 31, 2026 Filed Apr 1, 2026 23:00 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	Exercise / conversionCommon Stock	7,400	$14.18	$104,932.00	Disclosure SEC source: 0001193125-26-138372 · ownership.xml · nonDerivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:11 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	GrantNon-Qualified Stock Option (right to buy) · Derivative	165,440	$0.00 Strike: $39.21	$0.00	Disclosure SEC source: 0001772518-26-000002 · edgardoc.xml · derivative · entry 1 Ridloff Elena · CIK 0001772518 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,440 Underlying: Common Stock · 165,440 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
September 02, 2025 Filed Sep 3, 2025 21:16 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	SaleCommon Stock	8,836	$25.08	$221,606.88	Disclosure SEC source: 0002036042-25-000053 · edgardoc.xml · nonDerivative · entry 2 Ridloff Elena · CIK 0001772518 · CFO & Head of Corp. Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,532 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document
August 29, 2025 Filed Sep 3, 2025 21:16 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	SaleCommon Stock	748	$25.18	$18,834.64	Disclosure SEC source: 0002036042-25-000053 · edgardoc.xml · nonDerivative · entry 1 Ridloff Elena · CIK 0001772518 · CFO & Head of Corp. Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,368 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document
August 28, 2025 Filed Aug 28, 2025 21:40 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	SaleCommon Stock	16,098	$25.97	$418,065.06	Disclosure SEC source: 0002036042-25-000050 · edgardoc.xml · nonDerivative · entry 3 Ridloff Elena · CIK 0001772518 · CFO & Head of Corp. Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,116 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.01 to $26.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document
August 27, 2025 Filed Aug 28, 2025 21:40 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	SaleCommon Stock	3,618	$25.10	$90,811.80	Disclosure SEC source: 0002036042-25-000050 · edgardoc.xml · nonDerivative · entry 2 Ridloff Elena · CIK 0001772518 · CFO & Head of Corp. Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,214 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document
August 26, 2025 Filed Aug 28, 2025 21:40 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	SaleCommon Stock	3,700	$25.13	$92,981.00	Disclosure SEC source: 0002036042-25-000050 · edgardoc.xml · nonDerivative · entry 1 Ridloff Elena · CIK 0001772518 · CFO & Head of Corp. Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,832 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document
August 20, 2025 Filed Aug 21, 2025 20:04 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	SaleCommon Stock	17,500	$22.69	$397,075.00	Disclosure SEC source: 0001482981-25-000143 · edgardoc.xml · nonDerivative · entry 2 Ridloff Elena · CIK 0001772518 · CFO & Head of Corp. Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,532 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.0000 to $23.355, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document
August 19, 2025 Filed Aug 21, 2025 20:04 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	SaleCommon Stock	34,500	$21.08	$727,260.00	Disclosure SEC source: 0001482981-25-000143 · edgardoc.xml · nonDerivative · entry 1 Ridloff Elena · CIK 0001772518 · CFO & Head of Corp. Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,032 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.6700 to $21.5700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document
June 25, 2025 Filed Jun 27, 2025 01:00 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $46.47	$0.00	Disclosure SEC source: 0000950170-25-090579 · ownership.xml · derivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document
June 20, 2025 Filed Jun 20, 2025 16:15 UTC	Kronos Bio, Inc. KRON · Entity 78257	Disposition to issuerStock Option (Right to Buy) · Derivative	17,000	$0.00 Strike: $0.95	$0.00	Disclosure SEC source: 0001415889-25-017835 · form4-06202025_040631.xml · derivative · entry 7 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2034-06-24 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document
June 20, 2025 Filed Jun 20, 2025 16:15 UTC	Kronos Bio, Inc. KRON · Entity 78257	Disposition to issuerStock Option (Right to Buy) · Derivative	17,000	$0.00 Strike: $1.48	$0.00	Disclosure SEC source: 0001415889-25-017835 · form4-06202025_040631.xml · derivative · entry 6 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2033-06-21 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document
June 20, 2025 Filed Jun 20, 2025 16:15 UTC	Kronos Bio, Inc. KRON · Entity 78257	Disposition to issuerStock Option (Right to Buy) · Derivative	34,000	$0.00 Strike: $3.53	$0.00	Disclosure SEC source: 0001415889-25-017835 · form4-06202025_040631.xml · derivative · entry 5 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires 2032-06-21 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document
June 20, 2025 Filed Jun 20, 2025 16:15 UTC	Kronos Bio, Inc. KRON · Entity 78257	Disposition to issuerStock Option (Right to Buy) · Derivative	15,450	$0.00 Strike: $24.18	$0.00	Disclosure SEC source: 0001415889-25-017835 · form4-06202025_040631.xml · derivative · entry 4 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,450 shares Expires 2031-06-21 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document
June 20, 2025 Filed Jun 20, 2025 16:15 UTC	Kronos Bio, Inc. KRON · Entity 78257	Disposition to issuerStock Option (Right to Buy) · Derivative	26,871	$0.00 Strike: $13.35	$0.00	Disclosure SEC source: 0001415889-25-017835 · form4-06202025_040631.xml · derivative · entry 3 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,871 shares Expires 2030-09-10 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document
June 20, 2025 Filed Jun 20, 2025 16:15 UTC	Kronos Bio, Inc. KRON · Entity 78257	Disposition to issuerStock Option (Right to Buy) · Derivative	25,879	$0.00 Strike: $13.35	$0.00	Disclosure SEC source: 0001415889-25-017835 · form4-06202025_040631.xml · derivative · entry 2 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,879 shares Expires 2030-09-10 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document
June 20, 2025 Filed Jun 20, 2025 16:15 UTC	Kronos Bio, Inc. KRON · Entity 78257	OtherCommon Stock	25,296	$0.57	$14,418.72	Disclosure SEC source: 0001415889-25-017835 · form4-06202025_040631.xml · nonDerivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2 · shares: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. Read SEC document
June 11, 2025 Filed Jun 11, 2025 20:47 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	Exercise / conversionStock Option (Right to Buy) · Derivative	4,500	$0.00 Strike: $20.29	$0.00	Disclosure SEC source: 0000950170-25-084893 · ownership.xml · derivative · entry 3 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2032-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following the vesting commencement date of June 29, 2022, subject to the reporting person's continued service relationship through each vesting date. Read SEC document
June 11, 2025 Filed Jun 11, 2025 20:47 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	SaleCommon Stock	4,500	$50.00	$225,000.00	Disclosure SEC source: 0000950170-25-084893 · ownership.xml · nonDerivative · entry 2 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person. Read SEC document
June 11, 2025 Filed Jun 11, 2025 20:47 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	Exercise / conversionCommon Stock	4,500	$20.29	$91,305.00	Disclosure SEC source: 0000950170-25-084893 · ownership.xml · nonDerivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person. Read SEC document
June 03, 2025 Filed Jun 3, 2025 22:30 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	Exercise / conversionStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $27.67	$0.00	Disclosure SEC source: 0000950170-25-081200 · ownership.xml · derivative · entry 4 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2033-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document
June 03, 2025 Filed Jun 3, 2025 22:30 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	SaleCommon Stock	4,800	$47.00	$225,600.00	Disclosure SEC source: 0000950170-25-081200 · ownership.xml · nonDerivative · entry 3 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person. Read SEC document
June 03, 2025 Filed Jun 3, 2025 22:30 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	SaleCommon Stock	7,200	$45.50	$327,600.00	Disclosure SEC source: 0000950170-25-081200 · ownership.xml · nonDerivative · entry 2 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,800 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person. Read SEC document
June 03, 2025 Filed Jun 3, 2025 22:30 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	Exercise / conversionCommon Stock	12,000	$27.67	$332,040.00	Disclosure SEC source: 0000950170-25-081200 · ownership.xml · nonDerivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person. Read SEC document
February 06, 2025 Filed Feb 10, 2025 21:05 UTC	Sionna Therapeutics, Inc. SION · Entity 5996	GrantStock Option (Right to Buy) · Derivative	157,820	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0000950170-25-017032 · ownership.xml · derivative · entry 1 Ridloff Elena · CIK 0001772518 · CFO & Head of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,820 Underlying: Common Stock · 157,820 shares Expires 2035-02-05 F1 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
June 25, 2024 Filed Jun 26, 2024 16:37 UTC	Kronos Bio, Inc. KRON · Entity 78257	GrantStock Option (Right to Buy) · Derivative	17,000	$0.00 Strike: $0.95	$0.00	Disclosure SEC source: 0001415889-24-018239 · form4-06262024_080646.xml · derivative · entry 2 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document
June 25, 2024 Filed Jun 26, 2024 16:37 UTC	Kronos Bio, Inc. KRON · Entity 78257	GrantCommon Stock	11,333	$0.00	$0.00	Disclosure SEC source: 0001415889-24-018239 · form4-06262024_080646.xml · nonDerivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,296 Read SEC document
June 18, 2024 Filed Jun 20, 2024 21:00 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $31.20	$0.00	Disclosure SEC source: 0000950170-24-075711 · ownership.xml · derivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-17 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 18, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document
June 22, 2023 Filed Jun 26, 2023 16:15 UTC	Kronos Bio, Inc. KRON · Entity 78257	GrantStock Option (Right to Buy) · Derivative	17,000	$0.00 Strike: $1.48	$0.00	Disclosure SEC source: 0001209191-23-039696 · doc4.xml · derivative · entry 2 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document
June 22, 2023 Filed Jun 26, 2023 16:15 UTC	Kronos Bio, Inc. KRON · Entity 78257	GrantCommon Stock	11,333	$0.00	$0.00	Disclosure SEC source: 0001209191-23-039696 · doc4.xml · nonDerivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,963 Read SEC document
June 15, 2023 Filed Jun 20, 2023 20:15 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $27.67	$0.00	Disclosure SEC source: 0000899243-23-015968 · doc4.xml · derivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document
June 29, 2022 Filed Jul 1, 2022 20:05 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantStock Option (Right to Buy) · Derivative	9,000	$0.00 Strike: $20.29	$0.00	Disclosure SEC source: 0000899243-22-024748 · doc4.xml · derivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years beginning on June 29, 2022. Read SEC document
June 22, 2022 Filed Jun 29, 2022 16:10 UTC	Kronos Bio, Inc. KRON · Entity 78257	GrantStock Option (Right to Buy) · Derivative	34,000	$0.00 Strike: $3.53	$0.00	Disclosure SEC source: 0001209191-22-039779 · doc4.xml · derivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document
June 15, 2022 Filed Jun 16, 2022 20:05 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $14.18	$0.00	Disclosure SEC source: 0000899243-22-022792 · doc4.xml · derivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document
June 22, 2021 Filed Jun 23, 2021 21:20 UTC	Kronos Bio, Inc. KRON · Entity 78257	GrantStock Option (Right to Buy) · Derivative	15,450	$0.00 Strike: $24.18	$0.00	Disclosure SEC source: 0001209191-21-042888 · doc4.xml · derivative · entry 1 Ridloff Elena · CIK 0001772518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,450 Underlying: Common Stock · 15,450 shares Expires 2031-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.